327 related articles for article (PubMed ID: 28984301)
41. Nuclear β-Catenin Expression in the Context of Abnormal p53 Expression Indicates a Nonserous Histotype in Endometrial Carcinoma.
Keyhanian K; Yang EJ; Howitt BE
Int J Gynecol Pathol; 2023 Sep; 42(5):435-442. PubMed ID: 36731035
[TBL] [Abstract][Full Text] [Related]
42. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
43. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
[TBL] [Abstract][Full Text] [Related]
44. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.
Köbel M; Kang EY
Int J Gynecol Pathol; 2021 Jan; 40(1):32-40. PubMed ID: 33290354
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical characterization of endometrial carcinomas: endometrioid, serous and clear cell adenocarcinomas in association with genetic analysis.
Yasuda M
J Obstet Gynaecol Res; 2014 Dec; 40(12):2167-76. PubMed ID: 25363801
[TBL] [Abstract][Full Text] [Related]
46. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
47. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.
Felix AS; Stone RA; Bowser R; Chivukula M; Edwards RP; Weissfeld JL; Linkov F
Int J Gynecol Cancer; 2011 Jul; 21(5):877-84. PubMed ID: 21666484
[TBL] [Abstract][Full Text] [Related]
48. WT1 Positive Ovarian Endometrioid Tumors: Observations From Consult Cases and Strategies for Distinguishing From Serous Neoplasms.
Rajendran S; McCluggage WG
Int J Gynecol Pathol; 2022 Mar; 41(2):191-202. PubMed ID: 33782345
[TBL] [Abstract][Full Text] [Related]
49. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
50. PRAME Expression in Endometrioid and Serous Endometrial Carcinoma: A Potential Immunotherapeutic Target and Possible Diagnostic Pitfall.
Coppock JD; Gradecki SE; Mills AM
Int J Gynecol Pathol; 2023 Jan; 42(1):35-42. PubMed ID: 35512215
[TBL] [Abstract][Full Text] [Related]
51. Minor serous and clear cell components adversely affect prognosis in ''mixed-type'' endometrial carcinomas: a clinicopathologic study of 36 stage-I cases.
Quddus MR; Sung CJ; Zhang C; Lawrence WD
Reprod Sci; 2010 Jul; 17(7):673-8. PubMed ID: 20393071
[TBL] [Abstract][Full Text] [Related]
52. Use of mutation profiles to refine the classification of endometrial carcinomas.
McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
[TBL] [Abstract][Full Text] [Related]
53. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.
Demopoulos RI; Mesia AF; Mittal K; Vamvakas E
Int J Gynecol Pathol; 1999 Jul; 18(3):233-7. PubMed ID: 12092593
[TBL] [Abstract][Full Text] [Related]
54. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma.
Mhawech-Fauceglia P; Herrmann FR; Rai H; Tchabo N; Lele S; Izevbaye I; Odunsi K; Cheney RT
Am J Clin Pathol; 2010 Jun; 133(6):899-908. PubMed ID: 20472848
[TBL] [Abstract][Full Text] [Related]
55. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
[TBL] [Abstract][Full Text] [Related]
56. P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin.
Saad RS; Mashhour M; Noftech-Mozes S; Ismiil N; Dubé V; Ghorab Z; Faragalla H; Khalifa MA
Int J Gynecol Pathol; 2012 Jan; 31(1):57-65. PubMed ID: 22123724
[TBL] [Abstract][Full Text] [Related]
57. Evanescence of Endometrial Carcinomas in Hysterectomy Specimens: Observations on the "Vanishing Cancer" Phenomenon.
Bharani V; Rai B; Rajwanshi A; Gupta N; Dey P; Kalra J; Suri V; Srinivasan R
Int J Surg Pathol; 2019 Feb; 27(1):43-47. PubMed ID: 29944030
[TBL] [Abstract][Full Text] [Related]
58. Mammaglobin expression in gynecologic adenocarcinomas.
Hagemann IS; Pfeifer JD; Cao D
Hum Pathol; 2013 Apr; 44(4):628-35. PubMed ID: 23084633
[TBL] [Abstract][Full Text] [Related]
59. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
[TBL] [Abstract][Full Text] [Related]
60. Role of epithelial-mesenchymal transition factors in the histogenesis of uterine carcinomas.
Franceschi T; Durieux E; Morel AP; de Saint Hilaire P; Ray-Coquard I; Puisieux A; Devouassoux-Shisheboran M
Virchows Arch; 2019 Jul; 475(1):85-94. PubMed ID: 30739164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]